{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(23)"],"submitter":["Patel RR"],"pubmed_abstract":["<b>Background:</b> this study aims to evaluate the survival outcomes of patients suffering from head and neck synovial sarcoma (HNSS), especially in relation to patients with a localized disease at diagnosis. <b>Methods:</b> this retrospective chart review includes 57 patients diagnosed with primary HNSS between 1981 and 2020 who presented with a localized disease at diagnosis. Overall survival (OS) from diagnosis, local recurrence-free survival (LRFS), and metastasis-free survival (MFS) from the end of the primary tumor treatment are estimated. The Kaplan-Meier method, the log-rank test, and the Cox proportional hazards regression are used. <b>Results:</b> the 5-year OS, LRFS, and MFS are estimated at 80.4% (95% CI: 66.6%, 88.9%), 67.7% (95% CI: 50.0%, 80.4%), and 50.6% (95% CI: 34.4%, 64"],"journal":["Cancers"],"pagination":["4119"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11639992"],"repository":["biostudies-literature"],"pubmed_title":["Oncologic Outcomes in Patients with Localized, Primary Head and Neck Synovial Sarcoma."],"pmcid":["PMC11639992"],"pubmed_authors":["Lazar AJ","Goepfert RP","Lin PP","Bishop AJ","Amini B","Patel RR","Benjamin RS","Araujo DM","Gopalakrishnan V"],"additional_accession":[]},"is_claimable":false,"name":"Oncologic Outcomes in Patients with Localized, Primary Head and Neck Synovial Sarcoma.","description":"<b>Background:</b> this study aims to evaluate the survival outcomes of patients suffering from head and neck synovial sarcoma (HNSS), especially in relation to patients with a localized disease at diagnosis. <b>Methods:</b> this retrospective chart review includes 57 patients diagnosed with primary HNSS between 1981 and 2020 who presented with a localized disease at diagnosis. Overall survival (OS) from diagnosis, local recurrence-free survival (LRFS), and metastasis-free survival (MFS) from the end of the primary tumor treatment are estimated. The Kaplan-Meier method, the log-rank test, and the Cox proportional hazards regression are used. <b>Results:</b> the 5-year OS, LRFS, and MFS are estimated at 80.4% (95% CI: 66.6%, 88.9%), 67.7% (95% CI: 50.0%, 80.4%), and 50.6% (95% CI: 34.4%, 64","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-04T02:54:58.006Z","creation":"2025-04-04T02:54:58.006Z"},"accession":"S-EPMC11639992","cross_references":{"pubmed":["39682304"],"doi":["10.3390/cancers16234119"]}}